Warfarin or warfarin plus aspirin (Asp) v ASP after acute myocardial infarction at mean follow up of 1445 days ‡
| Outcomes | Comparisons | Event rates | RRR (95% CI) | NNT (CI) |
|---|---|---|---|---|
| ‡Abbreviations defined in glossary; RRR, RRI, NNT, NNH, and CI calculated from data in article. | ||||
| §Composite outcome = death, nonfatal reinfarction, or thromboembolic stroke, whichever occurred first. | ||||
| Composite outcome§ | Warfarin + Asp v Asp | 15% v 20% | 25% (11 to 37) | 20 (12 to 51) |
| Warfarin v Asp | 17% v 20% | 16% (1 to 29) | 30 (16 to 483) | |
| Nonfatal reinfarction | Warfarin + Asp v Asp | 6% v 10% | 41% (22 to 56) | 25 (16 to 53) |
| Warfarin v Asp | 7% v 10% | 24% (1 to 41) | 43 (22 to 1364) | |
| Thromboembolic stroke | Warfarin + Asp v Asp | 1% v 3% | 47% (6 to 70) | 80 (41 to 797) |
| Warfarin v Asp | Warfarin v Asp | 1% v 3% | 47% (6 to 70) | 80 (41 to 721) |
| RRI (CI) | NNH (CI) | |||
| Nonfatal major bleeding | Warfarin + Asp v Asp | 2% v 0.7% | 249% (63 to 650) | 60 (37 to 137) |
| Warfarin v Asp | 3% v 0.7% | 309% (93 to 767) | 49 (31 to 93) | |